Recognized for big strides in cancer immunotherapy treatments

LA JOLLA, Calif., September 27, 2018 -- INmune Bio Inc., an immunotherapy company developing treatments to reprogram the innate immune system to fight disease, announced today that it has been named on the final shortlist of 10 companies being considered for U.S. Private Company of the Year by Lifestars Awards, an organization in association with investment banking firm Jefferies that recognizes leaders in life sciences.

“We are delighted to be among the finalists for a Lifestars Award, receiving recognition by this high-profile organization alongside other companies with impressive accomplishments,” said INmune Bio co-founder and CEO Raymond J. Tesi, M.D. “INmune Bio has been making significant strides, with programs in the clinic and more news on the horizon.”

INmune Bio is providing a solution to important problems in immunotherapy. The company has two products: INB03TM, which is in a Phase 1 clinical trial, and INKmuneTM, which will be in the clinic early next year. Both products reprogram cells of the patient’s innate immune system, enlisting the often-ignored half of the immune system in the battle against cancer. Most products in immunotherapy today focus on the adaptive immunity and fail to address the complex biology of the tumor microenvironment. By targeting innate immunity and the immunosuppressive environment of the TME, INmune Bio’s novel approach to cancer immunotherapy should take the brakes off the immune system and may help solve the resistance to immunotherapy that has frustrated advancement in the field.

Lifestars Awards are a celebration of the success stories, innovations, transformational deals and the people, teams and organizations that play a critical role in the advancement of the life sciences industry each year across Europe and the United States. Lifestars hosts a signature evening networking event during the Jefferies Annual Healthcare Conference week in London, Europe's largest healthcare investment banking conference.

The Lifestars Awards will bring together over 500 global life science leaders, investors and researchers from the wider ecosystem to recognize the achievements of the industry. Winners will be announced during a gala dinner hosted at the Honourable Artillery Company in London on November 13. The event will support Unicef UK as the official charity beneficiary.

About INmune Bio Inc.

INmune Bio, Inc. is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer. Our drug candidates, INKmune™ and INB03™, can be used alone or with conventional therapies to help eliminate disease in a wide variety of cancers. They can also boost the effectiveness of other immunotherapies designed to enhance immune response to specific tumors.

The development of new immunotherapies is revolutionizing cancer care. INmune Bio is at the forefront of that revolution with novel products that take the brakes off of the most powerful weapon in the fight against cancer: the patient’s immune system. For more information, please visit

About Lifestars

The LifestarsTM Awards are organized by LSX, an influential community of senior life science decision makers. Through impactful events, powerful thought leadership content and unique networking opportunities, LSX exists to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare. For more information please visit

INmune Bio Contact:
David Moss, CFO
(858) 964-3720
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Antenna Group
Nechama Feuerstein
(201) 373-2228
This email address is being protected from spambots. You need JavaScript enabled to view it.

Lifestars Contact:
Taz Shariff
+44 (0) 203 637 5908
This email address is being protected from spambots. You need JavaScript enabled to view it.


This website uses cookies to facilitate the use of the website, improve its performance and security, and personalize the proposed content.